## Jacob S Ballon

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5342594/publications.pdf

Version: 2024-02-01

414414 471509 1,712 36 17 32 citations h-index g-index papers 36 36 36 2588 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Early Psychosis: Diagnosis and Treatment. Current Psychopharmacology, 2021, 10, 47-56.	0.3	2
2	Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia. Behavioural Brain Research, 2021, 402, 113101.	2.2	28
3	Cognition and Exercise. Journal of Cardiopulmonary Rehabilitation and Prevention, 2021, Publish Ahead of Print, 400-406.	2.1	4
4	Increased activation product of complement 4 protein in plasma of individuals with schizophrenia. Translational Psychiatry, 2021, 11, 486.	4.8	10
5	Suicide Reduction in Schizophrenia via Exercise (SUnRISE): study protocol for a multi-site, single-blind, randomized clinical trial of aerobic exercise for suicide risk reduction in individuals with schizophrenia. Trials, 2020, 21, 871.	1.6	3
6	Ethical Issues in Schizophrenia. Focus (American Psychiatric Publishing), 2020, 18, 428-431.	0.8	1
7	S107. VALIDATION OF THE NDSE, A NEW SELF REPORT SCALE FOR PEOPLE WITH PSYCHOSIS. Schizophrenia Bulletin, 2019, 45, S348-S348.	4.3	O
8	How genome-wide association studies (GWAS) made traditional candidate gene studies obsolete. Neuropsychopharmacology, 2019, 44, 1518-1523.	5.4	124
9	Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia. Journal of Psychiatry and Brain Science. 2019. 4	0.5	9
10	Therapeutic Potential of Physical Exercise in Early Psychosis. American Journal of Psychiatry, 2018, 175, 209-214.	7.2	11
11	Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. Journal of Psychopharmacology, 2018, 32, 533-540.	4.0	19
12	Genetic Correlation Profile of Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant (22q11.2) Cases of Schizophrenia. Schizophrenia Bulletin, 2018, 44, 1350-1361.	4.3	26
13	Clozapine Titration for People in Early Psychosis. Journal of Clinical Psychopharmacology, 2018, 38, 234-238.	1.4	4
14	The Impact of Hypomania on Aerobic Capacity and Cardiopulmonary Functioningâ€"A Case Report. Frontiers in Psychiatry, 2018, 9, 729.	2.6	0
15	Impact of age of onset of psychosis and engagement in higher education on duration of untreated psychosis. Journal of Mental Health, 2018, 27, 257-262.	1.9	9
16	Should Antipsychotic Medications for Schizophrenia Be Given for a Lifetime?. Journal of Clinical Psychopharmacology, 2017, 37, 125-130.	1.4	9
17	398. Aerobic Exercise Training in People with Schizophrenia: Neural, Cognitive, and Functional Benefits. Biological Psychiatry, 2017, 81, S162-S163.	1.3	0
18	Verbigeration: An overlooked symptom of a "forgotten syndrome�. Bipolar Disorders, 2017, 19, 710-712.	1.9	2

#	Article	IF	CITATIONS
19	Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia. Frontiers in Neuroscience, 2017, 11, 432.	2.8	55
20	The impact of aerobic exercise training on cardiopulmonary functioning in individuals with schizophrenia. Schizophrenia Research, 2016, 173, 116-117.	2.0	20
21	Aerobic exercise for cognitive deficits in schizophrenia — The impact of frequency, duration, and fidelity with target training intensity. Schizophrenia Research, 2016, 172, 213-215.	2.0	43
22	Use of Active-Play Video Games to Enhance Aerobic Fitness in Schizophrenia: Feasibility, Safety, and Adherence. Psychiatric Services, 2016, 67, 240-243.	2.0	26
23	The Impact of Aerobic Exercise on Brain-Derived Neurotrophic Factor and Neurocognition in Individuals With Schizophrenia: A Single-Blind, Randomized Clinical Trial. Schizophrenia Bulletin, 2015, 41, 859-868.	4.3	164
24	Aerobic fitness and body mass index in individuals with schizophrenia: Implications for neurocognition and daily functioning. Psychiatry Research, 2014, 220, 784-791.	3.3	80
25	Molecular pathophysiology of metabolic effects of antipsychotic medications. Trends in Endocrinology and Metabolism, 2014, 25, 593-600.	7.1	95
26	Emotional granularity and social functioning in individuals with schizophrenia: An experience sampling study. Journal of Psychiatric Research, 2014, 53, 141-148.	3.1	60
27	Polypharmacy for schizophrenia. Current Opinion in Psychiatry, 2013, 26, 208-213.	6.3	53
28	Advances in the Management of Treatment-Resistant Schizophrenia. Focus (American Psychiatric) Tj ETQq0 0 0	rgBT/Ove	erlogk 10 Tf 50
29	Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends in Pharmacological Sciences, 2010, 31, 381-390.	8.7	159
30	Personalized Medicine for Schizophrenia. , 2010, , 93-116.		0
31	Teaching Pearls from the Lost Art of Psychopharmacology. Journal of Psychiatric Practice, 2009, 15, 423-426.	0.7	8
32	Obstetrical complications in people at risk for developing schizophrenia. Schizophrenia Research, 2008, 98, 307-311.	2.0	20
33	Social functioning in young people at risk for schizophrenia. Psychiatry Research, 2007, 151, 29-35.	3.3	97
34	A Systematic Review of Modafinil. Journal of Clinical Psychiatry, 2006, 67, 554-566.	2.2	317
35	Venlafaxine and the Rapid Development of Anasarca. Journal of Clinical Psychopharmacology, 2006, 26, 97-98.	1.4	7
36	The Effects of Novel Antipsychotics on Glucose and Lipid Levels. Journal of Clinical Psychiatry, 2002, 63, 856-865.	2.2	239